Table 2.
Treatment characteristics.
| Patients | |
|---|---|
| N (%)/Median [Range] | |
| ICPI Treatment | |
| - Anti-PD-1 monotherapy | 214 (87%) |
| - Nivolumab | 182 (74%) |
| - Pembrolizumab | 23 (9%) |
| - Other | 9(4%) |
| - Anti-PD-1-based combination | 31 (13%) |
| - Ipilimumab–Nivolumab | 15 (6%) |
| - Other combination | 16 (7%) |
| Time on treatment (months) | 11.7 [0.7–13.1] |
| Interval from last surgery initiation of adjuvant treatment | |
| <12 weeks | 192 (78%) |
| >12 weeks | 53 (22%) |
| End of treatment | |
| - Completion | 129 (53%) |
| - Toxicity | 30 (12%) |
| - Relapse | 79 (32%) |
| - Ongoing | 2 (1%) |
| - Unknown | 5 (2%) |
ICPI: immune checkpoint inhibitor; PD-1: programmed death-1; N: number of patients.